Taysha Gene Therapies Files 8-K
Ticker: TSHA · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1806310
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: THSA
TL;DR
Taysha Gene Therapies filed an 8-K on 10/16/25, updating corporate info. No major news.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on October 16, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas, 75247, with a phone number of (214) 612-0000. The company is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This 8-K filing provides updated corporate information and signals ongoing regulatory compliance for Taysha Gene Therapies, Inc.
Risk Assessment
Risk Level: low — The filing is a routine corporate update and does not contain information that would immediately impact the company's stock price or operations.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- October 16, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247 (address) — Principal Executive Offices
- (214) 612-0000 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is for reporting other events and financial statements, as well as updating corporate information for Taysha Gene Therapies, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 16, 2025.
Where are Taysha Gene Therapies, Inc.'s principal executive offices located?
The principal executive offices of Taysha Gene Therapies, Inc. are located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
What is the company's telephone number?
The registrant's telephone number, including area code, is (214) 612-0000.
In which state is Taysha Gene Therapies, Inc. incorporated?
Taysha Gene Therapies, Inc. is incorporated in Delaware.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2025-10-16 16:10:20
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar
Filing Documents
- d35488d8k.htm (8-K) — 25KB
- d35488dex991.htm (EX-99.1) — 16KB
- 0001193125-25-241415.txt ( ) — 162KB
- tsha-20251016.xsd (EX-101.SCH) — 3KB
- tsha-20251016_lab.xml (EX-101.LAB) — 18KB
- tsha-20251016_pre.xml (EX-101.PRE) — 11KB
- d35488d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 16, 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. By: /s/ Kamran Alam Date: October 16, 2025 Kamran Alam Chief Financial Officer